Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending November 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility (PDMRs), or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of specific personnel transactions rather than a financial performance report.
Material Changes
The filing details a revaluation of the cash element of a notional investment held within the US Retirement Savings Plan. This resulted in an increase in the notional allocation of Ordinary share ADRs on November 3, 2011, at a price of $44.55 per ADR.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. It strictly reports on the transaction notification in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a) and (c).
Important Facts for Investors
- Transaction Type: Increase in notional allocation of GSK Ordinary share ADRs within the US Retirement Savings Plan.
- Transaction Date: November 3, 2011.
- Price per ADR: $44.55.
- Individuals Affected:
- Dr M M Slaoui (Director): 9 ADRs
- Dr K Slaoui (Connected Person): 8 ADRs
- Mr W C Louv (Director): 15 ADRs
- Dr D Pulman (Director): 27 ADRs
- Mr E J Gray (Director): 21 ADRs
- Mrs D P Connelly (Connected Person): 1 ADR
- Financial Data: No financial performance metrics are included in this specific filing.